Blood test reveals epigenetic modifications that could predict life-threatening type 2 diabetes complications

| | October 11, 2019
Image: AP Photo/Elaine Thompson
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Chronically high blood sugar levels in type 2 diabetes can damage tissues throughout the body, such as the nerves, eyes, or kidneys. These vascular complications are a leading cause of death for patients, and scientists have been working toward designing a noninvasive, simple means to detect them early on in the course of disease progression. Typically, clinicians rely on a series of separate tests—from urine screens and ultrasounds to eye examinations—to estimate the risk of developing complications. A blood test based on a biomarker associated with a range of such issues would save time for patients and be more convenient for clinicians.

In the latest development toward that goal, researchers have created a blood test that can predict the likelihood of a diabetes patient experiencing a vascular complication. The signals of present problems came from distinct patterns of epigenetic modifications known as hydroxymethylations on freely circulating DNA in the patients’ blood. In a pilot study of 62 participants, the scientists could accurately distinguish between those with and without complications based on those patterns, they report [October 1] in Clinical Chemistry.

Related article:  Meet Huda Zoghbi, pediatric neurologist working on rare diseases

“I thought it was novel,” remarks [epigeneticist] Philip Marsden.

Read full, original post: Blood-Based Epigenetic Screen Tests for Diabetes Complications

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend